

Notes

DEMALONYL DERIVATIVES OF
AZALOMYCIN F₄ AND
SCOPAFUNGINKAZUTOH TAKESAKO, TERUYA NAKAMURA,
AKIRA OBAYASHI, SHIGEO IWASAKI[†],
MICHIO NAMIKOSHI[†], SHIGENOBU OKUDA[†]
and TERUHIKO BEPPU^{††}Central Research Laboratories,
Takara Shuzo Co., Ltd.,
Seta, Otsu-shi, Shiga 520-21, Japan[†]Institute of Applied Microbiology,
University of Tokyo,
Bunkyo-ku, Tokyo 113, Japan^{††}Department of Agricultural Chemistry,
Faculty of Agriculture,
University of Tokyo,
Bunkyo-ku, Tokyo 113, Japan

(Received for publication January 9, 1986)


Azalomycins F₃, F₄ (**1**) and F₅,^{1,2)} scopafungin (niphimycin) (**2**)^{3,4)} (Fig. 1), copiamycin, neocopiamycin A^{5,6)} and guanidylfungins A and B⁷⁾ have similar chemical structures and antimicrobial spectra. These antibiotics are active against fungi and Gram-positive bacteria, and the activity is fungistatic even at high concentrations. Their structures are characterized by a macrocyclic polyhydroxyl lactone ring, an intramolecular six-membered hemiketal, a malonyl monoester, and a side chain with a terminal guanidine. Demalonyl derivatives of methylated guanidylfungin A and copiamycin have much stronger antimicrobial activity than the native compounds, and have fungicidal action.⁸⁾ This paper describes the synthesis, structure, and antimicrobial activity of methylation-demalonylation products of azalomycin (AZL) F₄ and scopafungin (SCPF) shown in Fig. 1.

AZL F₄ and SCPF were isolated from the culture broths of *Streptomyces hygroscopicus* var. *azalomyceticus* ATCC 13810 and *S. hygroscopicus* var. *enhygrus* NRRL 3664, respectively, by successive silica gel column chromatography with CHCl₃-MeOH-H₂O and with 2-butanol-H₂O followed by precipitation from aq acetone or aq MeOH.


AZL F₄ (MW 1,081) was treated with methanolic hydrogen chloride (MeOH-HCl) for about 20 minutes to give a mixture of methylated products (SI-MS *m/z* 1,110 (M+H)). The mixture was then treated with 0.5 N KOH overnight in MeOH-H₂O (1:1) to give a mixture of demalonyl products, **3** (yield 35%, mp 121~126°C, SI-MS *m/z* 1,024 (M+H)), which was separated into **3a** and **3b** by preparative ODS-silica gel HPLC. **3a**: ¹H NMR (400 MHz, CD₃OD) δ 7.10 (1H, d, *J*=11 Hz, H-3), 6.45 (1H, dd, *J*=11, 14 Hz, H-4), 6.25 (1H, dd, *J*=11, 14 Hz, H-32), 6.10 (1H, dd, *J*=14, 8 Hz, H-5), 5.95 (1H, d, *J*=11 Hz, H-31), 5.5~5.35 (3H, H-33, 40, 41), 4.81 (1H, m, H-35), 4.2~3.65 (10H), 3.52 (1H, d, *J*=9 Hz, H-18), 3.25 (3H, s, OCH₃), 3.17 (2H, t, *J*=6 Hz, H₂-44), 3.14 (3H, s, OCH₃), 2.84 (3H, s, NCH₃), 2.58 (1H, m), 2.46 (1H, m), 1.90 (3H, s, H₃-45), 1.59 (3H, s, H₃-49), 2.1~1.1 (31H), 1.12 (3H, d, *J*=7 Hz), 1.03 (3H, d, *J*=7 Hz), 0.96 (3H, d, *J*=7 Hz), 0.92 (3H, d, *J*=7 Hz), 0.89 (3H, d, *J*=7 Hz); ¹³C NMR (100 MHz, CD₃OD) δ 169.2 (C-1), 157.5 (C=N), 145.0, 139.3, 137.0, 135.3, 132.0, 129.4, 128.6, 127.4, 127.0, 126.3, 102.1 (C-17), 86.4, 80.3, 76.5, 75.3, 74.8, 72.4, 71.5, 69.0, 67.4, 66.3, 65.8, 65.7, 55.9, 49.6, 47.7, 47.1, 46.1, 44.7, 44.1, 42.7, 41.8, 41.1, 41.0, 40.6, 39.3, 35.4, 35.0, 34.5, 33.5, 33.2, 30.3, 30.1, 29.7, 28.2, 27.8, 17.6, 16.9, 14.8, 14.0, 12.8, 11.3, 10.7. Product **3b** was found to be a mixture of some isomers at its methylated positions and other positions from its ¹H and ¹³C NMR.

As indicated by the spectral data described above, the methylated AZL F₄ and **3** should have been methylated at two positions, one of which was at C-17. To determine the other methylated position, **3** was decomposed by ozonolysis followed by NaBH₄ reduction. Then the product was subjected to NaIO₄ oxidation, and further NaBH₄ reduction. The mixture of degradation products obtained was acetylated with acetic anhydride in the presence of pyridine and 4-dimethylaminopyridine, and separated by preparative HPLC using ODS-silica gel and silica gel to give compounds **5**~**9** (Fig. 2).

Compounds **5** and **6** were identified spectroscopically and chromatographically as the same degradation products obtained from AZL

Fig. 1. Structures of AZL F₄, SCPF and their demalonyl derivatives.

AZL F₄ (1) R₁ = H, R₂ = COCH₂COOH, R₃ = H
 3 R₁ = CH₃, R₂ = H, R₃ = CH₃



SCPF (2) R₁ = H, R₂ = COCH₂COOH
 4 R₁ = CH₃, R₂ = H


Fig. 2. Degradation products of 3 by O₃ - NaBH₄ - NaIO₄ - NaBH₄.

Table 1. ^1H NMR of **7** (400 MHz in CDCl_3).

Chemical shift (ppm)	Intensity, multiplicity, J (Hz)	Assignment
5.05 (5.02)	1H, m, $J_{30,40}=7$ (7), $J_{30,29}=3$ (5)	H-30
5.12~4.9	4H	H-21, 23, 25, 27
4.08	2H, t, $J_{10,20}=7$	H ₂ -19
3.39 (3.41, 3.38, 3.37)	3H, s	OCH_3
3.15 (3.30)	1H, m, $J_{29,30}=3$ (5)	H-29
2.06, 2.05, 2.04, 2.01	18H, 6s	Acetyl methyls
2.1~1.5	10H	
1.17 (1.20, 1.19, 1.18)	3H, d, $J_{40,30}=7$ (7)	H ₃ -49

Signals in parentheses were split due to stereo-isomerisms at C-29 and 30.

Table 2. Antifungal activity of AZL F₄, SCPF and their demalonyl derivatives against *Candida albicans* Yu 1200 and *Aspergillus fumigatus* IAM 2046.

Compounds	MIC ($\mu\text{g/ml}$)		MCC ($\mu\text{g/ml}$)	
	<i>C. albicans</i>	<i>A. fumigatus</i>	<i>C. albicans</i>	<i>A. fumigatus</i>
AZL F ₄ (1)	12.5	25	>200	>200
3	12.5	12.5	25	50
SCPF (2)	12.5	25	>200	>200
4	6.25	6.25	12.5	12.5

MIC and MCC were determined by the method described in ref 8.

F_{4a} (compounds **8a** and **16a**, respectively, in ref 9). The structure of **7** was elucidated spectroscopically. Its ^1H NMR (Table 1) indicated that the other methylated position was the hydroxyl group at C-29. Product **7** was a mixture of stereo-isomers at C-29 and 30, which should be brought about in the methoxyl group substitution at C-29 with MeOH-HCl and in ozonolysis of Δ^{30} followed by NaBH_4 treatment. The structures of **8** and **9** were elucidated by comparison of their ^1H NMR spectra with those of **6** and **7**. **8**: ^1H NMR (200 MHz, CDCl_3) δ 5.2~4.7 (7H), 4.08 (2H, t, H₂-29), 4.00 (2H, t, H₂-5), 4.25~3.8 (5H), 3.35 (3.30)^a (3H, s, OCH_3), 2.07, 2.06, 2.05, 2.03, 2.01 and 2.00 (33H, 11s, acetyl methyls), 2.2~1.0 (21H), 0.95 (6H, 2d, $J=7$ Hz, H₃-46, 47), 0.82 (3H, d, $J=7$ Hz, H₃-48). **9**: ^1H NMR (200 MHz, CDCl_3) δ 5.2~4.7 (8H), 4.00 (2H, H₂-5), 4.25~3.65 (5H), 3.38 (3.41)^a (3H, s, C-29- OCH_3), 3.35 (3.30)^a (3H, s, C-17- OCH_3), 3.15 (1H, H-29), 2.07, 2.06, 2.04, 2.03, 2.01 and 2.00 (33H, 11s, acetyl methyls), 2.2~1.0 (21H), 1.17 (1.18)^a (3H, d, $J=7$ Hz, H₃-49), 0.95 (6H, 2d, $J=7$ Hz, H₃-46, 47), 0.82 (3H, d, $J=7$ Hz, H₃-48).

SCPF (MW 1,141) was similarly treated with

^a The signals in parentheses were split because of stereo-isomerisms at C-17, 29 or 30.

MeOH-HCl and then with KOH to obtain **4** yield 65%: mp 123~126°C; SI-MS m/z 1,070 (M+H); ^{13}C NMR (25 MHz, CD_3OD) δ 176.4 (C-1), 158.1 (C=N), 137.0, 135.0, 132.8, 132.1, 129.8, 102.5 (C-17), 79.5, 76.6, 76.0, 75.2, 72.1, 69.3, 68.9, 66.2, 66.1, 45.3, 45.0, 43.5, 42.6, 41.9, 41.0, 40.8, 39.0, 37.5, 35.4, 33.8, 32.4, 30.5, 29.7, 28.3, 27.8, 20.3, 17.7, 16.9, 14.9, 14.5, 10.9, 10.3.

The allylic hydroxyl groups at C-29 of AZL F₃ and F₅ were also methylated in addition to the hemiketal hydroxyl group at C-17 (data not shown), whereas such allylic hydroxyl groups of SCPF (at C-3 and C-29) and of the other related antibiotics were not. The difference in the reactivities of these allylic hydroxyl groups toward MeOH-HCl treatment may be caused by steric factors at adjacent carbon atoms (C-28 of AZL F₃, C-2 and C-28 of SCPF and of guanidyl-fungins, and C-26 of copiamycins) on which only AZL F₃ are not substituted by a methyl group.

The demalonyl derivatives thus obtained were soluble in H₂O (10~30 mg/ml). The antimicrobial activities of these derivatives are shown in Table 2. Compounds **3** and **4** were slightly more active than their native compounds in their MICs. However, these demalonyl derivatives were highly fungicidal, though the mother compounds were fungistatic even at high con-

centrations, as in the case of guanidylfungin A and copiamycin.⁶⁾

References

- 1) IWASAKI, S.; M. NAMIKOSHI, K. SASAKI, K. FUKUSHIMA & S. OKUDA: Studies on macrocyclic lactone antibiotics. V. The structures of azalomycins F_{3a} and F_{5a}. Chem. Pharm. Bull. 30: 4006~4014, 1982
- 2) IWASAKI, S.; M. NAMIKOSHI, K. SASAKI, M. AMANO, K. FUKUSHIMA, S. NOZOE & S. OKUDA: Studies on macrocyclic lactone antibiotics. III. Skeletal structure of azalomycin F_{4a}. Chem. Pharm. Bull. 30: 1669~1673, 1982
- 3) SAMAIN, D.; J. C. COOK, Jr. & K. L. RINEHART, Jr.: Structure of scopafungin, a potent non-polyene antifungal antibiotic. J. Am. Chem. Soc. 104: 4129~4141, 1982
- 4) GASSMANN, P.; L. HAGMANN, W. KELLER-SCHIERLEIN & D. SAMAIN: Versuche zur Strukturaufklärung von Niphimycin. 3. Identität von Scopafungin mit Niphimycin I und Lage des Malonylrestes in Niphimycin und Copiamycin. Helv. Chim. Acta 67: 696~705, 1984
- 5) FUKUSHIMA, K.; T. ARAI, S. IWASAKI, M. NAMIKOSHI & S. OKUDA: Studies on macrocyclic lactone antibiotics. VI. Skeletal structure of copiamycin. J. Antibiotics 35: 1480~1494, 1982
- 6) ARAI, T.; J. UNO, I. HORIMI & K. FUKUSHIMA: Isolation of neocopiamycin A from *Streptomyces hygroscopicus* var. *crystallogenes*, the copiamycin source. J. Antibiotics 37: 103~109, 1984
- 7) TAKESAKO, K. & T. BEPPU: Studies on new antifungal antibiotics, guanidylfungins A and B. II. Structure elucidation and biosynthesis. J. Antibiotics 37: 1170~1186, 1984
- 8) TAKESAKO, K.; T. BEPPU, T. NAKAMURA & A. OBAYASHI: Demalonyl derivatives of guanidylfungin A and copiamycin: Their synthesis and antifungal activity. J. Antibiotics 38: 1363~1370, 1985
- 9) NAMIKOSHI, M.; S. IWASAKI, K. SASAKI, M. YANO, K. FUKUSHIMA, S. NOZOE & S. OKUDA: Studies on macrocyclic lactone antibiotics. II. Partial structures of azalomycin F_{4a}. Chem. Pharm. Bull. 30: 1658~1668, 1982